Responsibilities:

? Lead biology efforts to advance projects for pre-clinical and clinical studies in novel IO drug discovery based on GV20’s in-house novel IO drug discovery platform
? Utilize expertise to independently design, execute and analyze in vitro and in vivo experiments to support the project transition and investigate the immunology mechanisms.
? Explore, develop and apply novel preclinical assays, screenings and tumor model systems to identify new immune-oncology targets and understand in-depth mechanisms.
? Supervise research associates and/or scientists
? Effectively collaborate Oncology group, partner lines, CRO and academic to advance portfolio projects.

Essential Requirements

A PhD, or equivalent experience, in immunology and/or immuno-oncology.

• Experience of a range of in vitro skills analyzing human immune cell function e.g. multiparameter flow cytometry, ELISA, primary immune cell co-cultures, molecular biology skills including transcriptomics, assessment of intracellular signaling and generation of engineered cell lines
• Strong interpersonal, influencing, negotiating and collaboration skills together with evidence of having used these to support problem solving and delivery in a team focused, collaborative environment.
• Depth of understanding and enthusiasm for immunology and immuno-oncology
• Proven track record of success in your research
• Data processing, statistical analysis and interpretation.
• Experience preparing written scientific reports (e.g. manuscripts) and oral presentations (e.g. slides, posters).

Desirable Requirements

• We would encourage applications from you if you have experience in immuno-metabolism, myeloid biology and/or bioinformatics (e.g. experience with transcriptomic data, visualizing/quantitating multi-parameter flow data).
• Experience working with patient-derived tumors/TILs an advantage
• Knowledge of the processes around drug discovery

• Publications in top tier scientific journals

寻百会生物科技 简介

上海寻百会生物科技有限公司于2016年创立于上海张江药谷，是一家致力于通过整合基因组学、生物信息方法来筛选癌症药物的有效靶点，并开发新型肿瘤免疫治疗抗体药物的原研新药开发公司。寻百会生物科技的创始人是美国哈佛大学刘小乐教授，依托于刘教授团队建立的肿瘤功能基因组学和生物信息学技术，寻百会已拥有CRISPR 全基因组筛选平台，肿瘤分子分型平台和抗体研发平台等数个专有的新药研发平台。并结合人工智能与生物大数据挖掘技术，研发新一代免疫治疗抗体药物，目前公司已有多个原创新药正在临床前研发阶段，寻百会致力于推进肿瘤治疗方法的研发速度和准度，同时加快肿瘤治疗药物开发产业的研发效率。

上班地址：蔡伦路781号801室